Specific-class Skin Side-effects of Drugs Might Compromise Blinding in Randomized Controlled Trials

Authors

  • Giao Do-Pham Department of Dermatology, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Henri Mondor, Paris, France; Department of Internal Medicine, Intercommunal Creteil Hospital, Créteil, France
  • Annabel Maruani Universities of Tours et Nantes, INSERM 1246-SPHERE, Nantes, France; Department of Dermatology, Centre Hospitalier Régional Universitaire (CHRU) Tours, Tours, France
  • Sophie Leducq Universities of Tours et Nantes, INSERM 1246-SPHERE, Nantes, France; Department of Dermatology, Centre Hospitalier Régional Universitaire (CHRU) Tours, Tours, France
  • Bruno Giraudeau Universities of Tours et Nantes, INSERM 1246-SPHERE, Nantes, France; INSERM CIC 1415, CHRU Tours, Tours, France
  • Olivier Chosidow Department of Dermatology, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Henri Mondor, Paris, France; Universities of Tours et Nantes, INSERM 1246-SPHERE, Nantes, France

DOI:

https://doi.org/10.2340/actadv.v103.3364

Keywords:

blinding, randomized controlled trial, side effects

Abstract

Abstract is missing (Short communication)

Downloads

Download data is not yet available.

References

Bello S, Moustgaard H, Hróbjartsson A. Unreported formal assessment of unblinding occurred in 4 of 10 randomized clinical trials, unreported loss of blinding in 1 of 10 trials. J Clin Epidemiol 2017; 81: 42-50.

https://doi.org/10.1016/j.jclinepi.2016.08.002 DOI: https://doi.org/10.1016/j.jclinepi.2016.08.002

Savović J, Jones HE, Altman DG, Harris RJ, Juni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Ann Intern Med 2012; 157: 429-438.

https://doi.org/10.7326/0003-4819-157-6-201209180-00537 DOI: https://doi.org/10.7326/0003-4819-157-6-201209180-00537

Boutron I, Estellat C, Guittet L, Dechartres A, Sackett DL, Hróbjartsson A, et al. Methods of blinding in reports of randomized controlled trials assessing pharmacologic treatments: a systematic review. PloS Med 2006; 3: e425.

https://doi.org/10.1371/journal.pmed.0030425 DOI: https://doi.org/10.1371/journal.pmed.0030425

Hróbjartsson A, Emanuelsson F, Skou Thomsen AS, Hilden J, Brorson S. Bias due to lack of patient blinding in clinical trials. A systematic review of trials randomizing patients to blind and nonblind sub-studies. Int J Epidemiol 2014; 43: 1272-1283.

https://doi.org/10.1093/ije/dyu115 DOI: https://doi.org/10.1093/ije/dyu115

Lacouture ME, Sibaud V, Anadkat MJ, Kaffenberger B, Leventhal J, Guindon K, et al. Dermatologic adverse events associated with selective fibroblast growth factor receptor inhibitors: overview, prevention, and management guidelines. Oncologist 2021; 26: e316-e326.

https://doi.org/10.1002/onco.13552 DOI: https://doi.org/10.1002/onco.13552

Khalil S, Bardawil T, Stephan C, Darwiche N, Abbas O, Kibbi AG, et al. Retinoids: a journey from the molecular structures and mechanisms of action to clinical uses in dermatology and adverse effects. J Dermatolog Treat 2017; 28: 684-696.

https://doi.org/10.1080/09546634.2017.1309349 DOI: https://doi.org/10.1080/09546634.2017.1309349

Moustgaard H, Bello S, Miller FG, Hróbjartsson A. Subjective and objective outcomes in randomized clinical trials: definitions differed in methods publications and were often absent from trial reports. J Clin Epidemiol 2014; 67: 1327-1334.

https://doi.org/10.1016/j.jclinepi.2014.06.020 DOI: https://doi.org/10.1016/j.jclinepi.2014.06.020

Ueyama A, Yamamoto M, Tsujii K, Furue Y, Imura C, Shichijo M, et al. Mechanism of pathogenesis of imiquimod-induced skin inflammation in the mouse: a role for interferon-alpha in dendritic cell activation by imiquimod. J Dermatol 2014; 41: 135-143.

https://doi.org/10.1111/1346-8138.12367 DOI: https://doi.org/10.1111/1346-8138.12367

Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, Guibaud L, Baselga E, Posiunas G, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med 2015; 372: 735-746.

https://doi.org/10.1056/NEJMoa1404710 DOI: https://doi.org/10.1056/NEJMoa1404710

Leducq S, Samimi M, Bernier C, Soria A, Amsler E, Staumont-Sallé D, et al. Efficacy and safety of methotrexate versus placebo as add-on therapy to H1 antihistamines for patients with difficult-to-treat chronic spontaneous urticaria: a randomized, controlled trial. J Am Acad Dermatol 2020; 82: 240-243.

https://doi.org/10.1016/j.jaad.2019.07.097 DOI: https://doi.org/10.1016/j.jaad.2019.07.097

Howick J, Webster R, Kirby N, Hood K. Rapid overview of systematic reviews of nocebo effects reported by patients taking placebos in clinical trials. Trials 2018; 19: 674.

https://doi.org/10.1186/s13063-018-3042-4 DOI: https://doi.org/10.1186/s13063-018-3042-4

Golder S, Loke Y, McIntosh HM. Poor reporting and inadequate searches were apparent in systematic reviews of adverse effects. J Clin Epidemiol 2008; 61: 440-448.

https://doi.org/10.1016/j.jclinepi.2007.06.005 DOI: https://doi.org/10.1016/j.jclinepi.2007.06.005

Pitrou I, Boutron I, Ahmad N, Ravaud P. Reporting of safety results in published reports of randomized controlled trials. Arch Intern Med 2009; 169: 1756-1761.

https://doi.org/10.1001/archinternmed.2009.306 DOI: https://doi.org/10.1001/archinternmed.2009.306

Additional Files

Published

2023-02-14

How to Cite

Do-Pham, G., Maruani, A., Leducq, S., Giraudeau, B., & Chosidow, O. (2023). Specific-class Skin Side-effects of Drugs Might Compromise Blinding in Randomized Controlled Trials. Acta Dermato-Venereologica, 103, adv00867. https://doi.org/10.2340/actadv.v103.3364

Issue

Section

Short Communication

Categories